Peroxisome Proliferator-activated Receptor-γ Represses GLUT4 Promoter Activity in Primary Adipocytes, and Rosiglitazone Alleviates This Effect

This publication has 34 references indexed in Scilit:

• PPAR-γ agonists: therapeutic role in diabetes, inflammation and cancer
  Trends in Pharmacological Sciences, 2000
• Rosiglitazone
  Drugs, 1999
• Troglitazone
  Drugs, 1997
• Chromosomal Localization and Partial Genomic Structure of the Human Peroxisome Proliferator Activated Receptor-Gamma (hPPARγ) Gene
  Biochemical and Biophysical Research Communications, 1997
• Inhibition of Adipogenesis Through MAP Kinase-Mediated Phosphorylation of PPARγ
  Science, 1996
• Regulation of GLUT4 Gene Expression by Arachidonic Acid: EVIDENCE FOR MULTIPLE PATHWAYS, ONE OF WHICH REQUIRES OXIDATION TO PROSTAGLANDIN E2
  Published by Elsevier ,1996
• Modulation of the activity of glucose transporters (GLUT) in the aged/obese rat adipocyte: suppressed function, but enhanced intrinsic activity of GLUT
  Endocrinology, 1995
• Glycemic improvement in diabetic db/db mice by overexpression of the human insulin-regulatable glucose transporter (GLUT4).
  Journal of Clinical Investigation, 1995
• mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer.
  Genes & Development, 1994
• A possible mechanism of insulin resistance in the rat adipose cell in streptozotocin-induced diabetes mellitus. Depletion of intracellular glucose transport systems.
  Journal of Clinical Investigation, 1981